Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab.

about

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.

P2860

Q50323773-E7F2F747-E376-48E5-BE51-55A87533CD53

P2860

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab.

Item

http://www.wikidata.org/entity/Q42340113

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Serological markers associated ...... hritis treated with rituximab.

@en

Serological markers associated ...... hritis treated with rituximab.

@nl

type

Item

label

Serological markers associated ...... hritis treated with rituximab.

@en

Serological markers associated ...... hritis treated with rituximab.

@nl

prefLabel

Serological markers associated ...... hritis treated with rituximab.

@en

Serological markers associated ...... hritis treated with rituximab.

@nl

P1476

Serological markers associated ...... hritis treated with rituximab.

@en

P2093

Barbara Kroegler

http://www.w3.org/2001/XMLSchema#string

Maria Sole Chimenti

http://www.w3.org/2001/XMLSchema#string

Paola Conigliaro

http://www.w3.org/2001/XMLSchema#string

Paola Triggianese

http://www.w3.org/2001/XMLSchema#string

Ramona Lucchetti

http://www.w3.org/2001/XMLSchema#string

Roberto Perricone

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

The Disease Activity Score and the EULAR response criteria.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

The type I IFN system in rheumatoid arthritis.

Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis

P304

53-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0300060515593240

http://www.w3.org/2001/XMLSchema#string

P433

1 suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27683140

http://www.w3.org/2001/XMLSchema#string

P932

5536544

http://www.w3.org/2001/XMLSchema#string

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab.

about

P2860

P2860

Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932